ClinicalTrials.gg
CompletedNCT02384538Updated Aug 11, 2017Results posted

A Phase 2a Study Evaluating the Safety and Efficacy of ABT-981 in Patients With Erosive Hand Osteoarthritis

A Phase 2 interventional study of ABT-981 and Placebo for ABT-981 in Erosive Hand Osteoarthritis, sponsored by AbbVie. Completed. Open to participants aged 35 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-08-11.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
35 Years to 80 Years
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled study to compare the safety and efficacy of ABT-981 to placebo in subjects with erosive hand osteoarthritis.

02

Conditions studied

  • Erosive Hand Osteoarthritis

Keywords

  • Osteoarthritis
  • Joint diseases
  • Musculoskeletal diseases
  • Rheumatic diseases
  • Arthritis
  • Osteoarthritis, Hand
03

In context

Osteoarthritis

2,975 studies on the registry are indexed under Osteoarthritis; 436 are open to participants now.

This study's enrollment of 132 is above the median of 80 across 2,240 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female between the ages of 35 to 80.
  2. Must fulfill 1990 American College of Rheumatology (ACR) hand osteoarthritis (OA) criteria
  3. Must have radiographic evidence of erosive hand OA
  4. Have one or more clinical signs and symptoms of active inflammation in at least three hand joints
  5. Subject Assessment of Hand Pain Intensity in at least one hand is ≥ 6.

Exclusion criteria

Exclusion Criteria:

  1. Previous exposure to any anti-interleukin-1 treatment, to within 1 month prior to Screening, to intra-articular hyaluronic acid injection into hand joint(s) within 6 months prior to Screening, to any biologic therapy within 1 month or 5 half-lives (whichever is longer) prior to the first dose of study drug, OR current use of immunosuppressive oral medications within 3 months or 5 half-lives (whichever is longer) prior to the first dose of study drug.
  2. \< 2,000 per mm3
  3. Diagnosis of one or more of the following:

    • Fibromyalgia,
    • Inflammatory arthritis such as rheumatoid arthritis, peripheral seronegative spondyloarthropathy,
    • Psoriatic arthritis, psoriasis,
    • Microcrystalline (including gout and pseudo gout) arthritis affecting the hands,
    • Any OA of the hands due to an infectious origin or acute traumatic episode, secondary OA or OA linked to cartilage and bone dysplasia,
    • Other chronic painful syndromes that could interfere with assessment of pain at the hand(s).
  4. Any uncontrolled medical illness or an unstable treatment or therapy.
  5. Any reason that prohibits a subject to undergo an MRI.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
132 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for ABT-981 every two weeks (Q2W) for 24 weeks.

    Biological: Placebo for ABT-981

  • Experimental
    ABT-981

    ABT-981 200 mg every two weeks (Q2W) for 24 weeks.

    Biological: ABT-981

Interventions

  • BiologicalABT-981

    ABT-981 administered by subcutaneous injection

    Also known as: lutikizumab

  • BiologicalPlacebo for ABT-981

    Placebo for ABT-981 administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16

    The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. Last Observation Carried Forward (LOCF): Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

    Time frame: Week 0 (Baseline), Week 16

Secondary outcomes

  1. Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Each Visit

    The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

    Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26

  2. Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Physical Function Subdomain Score: Change From Baseline to Each Visit

    The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The physical function subdomain score ranges from 0 to 90; lower scores indicate better status. A decrease in the physical function subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

    Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26

  3. Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Stiffness Subdomain Score: Change From Baseline to Each Visit

    The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The stiffness subdomain score ranges from 0 to 10; lower scores indicate better status. A decrease in the stiffness subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

    Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26

  4. Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Total Score: Change From Baseline to Each Visit

    The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The total score ranges from 0 to 150; lower scores indicate better status. A decrease in the total score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

    Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26

  5. Participant Assessment of Index Hand Pain Intensity Using Numeric Rating Scale (NRS-11): Change From Baseline to Each Visit

    Participants rated the pain intensity of each hand during the previous 48 hours using an 11-point scale (NRS-11). The change from baseline to each visit in NRS-11 in the index hand (the hand with the most disease) are presented. Scores range from 0 to 10 points, with higher scores indicating greater pain intensity. A decrease in the NRS-11 score represents a decrease in pain intensity.

    Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26

  6. Patient Global Assessment of Hand Osteoarthritis (OA) Status by NRS-11: Change From Baseline to Each Visit

    Participants were asked how much they were affected by hand OA by responding to the question "Considering all the ways your hand OA affects you, how have you been during the last 48 hours?" using an 11-point scale (NRS-11). Scores range from 0 to 10 points, with higher scores indicating greater effect of hand OA on the participant. A decrease in the NRS-11 score represents an improvement the effect of hand OA on the participant.

    Time frame: Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26

07

Results

Posted Jul 13, 2017

Participant flow

Participant flow — Overall Study
MilestonePlaceboABT-981
Started6764
Completed6149
Not completed615
Withdrew: Adverse event14
Withdrew: Lack of efficacy44
Withdrew: Withdrew consent04
Withdrew: Other13

Outcome measures

PrimaryAustralian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16

The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. Last Observation Carried Forward (LOCF): Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

Time frame:
Week 0 (Baseline), Week 16
Reported as:
Least squares mean · units on a scale
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16
units on a scalePlaceboABT-981
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Week 16-10.74 (-15.433 to -6.045)-9.22 (-13.798 to -4.645)
Statistical analysis
  • Placebo vs ABT-981 · ANCOVA · p = 0.386 (P-value for test of difference in change from baseline between ABT-981 dose group and placebo is from an ANCOVA model with treatment group and country as the main factors and baseline as a covariate.) · Ls mean difference: 1.52 · 95% CI -1.944 to 4.990
SecondaryAustralian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Each Visit

The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The pain subdomain score ranges from 0 to 50; lower scores indicate better status. A decrease in the pain subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

Time frame:
Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Reported as:
Least squares mean · units on a scale
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Pain Subdomain Score: Change From Baseline to Each Visit
units on a scalePlaceboABT-981
Week 2-3.25 (-7.058 to 0.550)-3.27 (-6.983 to 0.438)
Week 4-5.01 (-9.144 to -0.885)-4.26 (-8.280 to -0.237)
Week 8-8.90 (-13.065 to -4.744)-6.44 (-10.488 to -2.384)
Week 12-8.31 (-12.593 to -4.030)-5.64 (-9.809 to -1.469)
Week 16-10.74 (-15.443 to -6.045)-9.22 (-13.798 to -4.645)
Week 20-7.28 (-11.969 to -2.591)-8.37 (-12.941 to -3.807)
Week 26-8.76 (-13.782 to -3.737)-10.37 (-15.264 to -5.481)
SecondaryAustralian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Physical Function Subdomain Score: Change From Baseline to Each Visit

The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The physical function subdomain score ranges from 0 to 90; lower scores indicate better status. A decrease in the physical function subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

Time frame:
Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Reported as:
Least squares mean · units on a scale
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Physical Function Subdomain Score: Change From Baseline to Each Visit
units on a scalePlaceboABT-981
Week 2-6.23 (-13.098 to 0.630)-4.79 (-11.440 to 1.861)
Week 4-8.43 (-15.879 to -0.974)-7.04 (-14.249 to 0.177)
Week 8-14.25 (-21.729 to -6.763)-8.97 (-16.211 to -1.725)
Week 12-12.54 (-20.140 to -4.947)-8.53 (-15.887 to -1.182)
Week 16-17.18 (-24.938 to -9.431)-14.64 (-22.142 to -7.133)
Week 20-11.50 (-19.415 to -3.584)-12.53 (-20.189 to -4.867)
Week 26-14.25 (-22.523 to -5.978)-16.39 (-24.402 to -8.388)
Statistical analysis
  • Placebo vs ABT-981 · ANCOVA · p = 0.383 (P-value for test of difference in change from baseline between ABT-981 dose group and placebo is from an ANCOVA model with treatment group and country as the main factors and baseline as a covariate.) · Ls mean difference: 2.55 · 95% CI -3.214 to 8.308
SecondaryAustralian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Stiffness Subdomain Score: Change From Baseline to Each Visit

The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The stiffness subdomain score ranges from 0 to 10; lower scores indicate better status. A decrease in the stiffness subdomain score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

Time frame:
Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Reported as:
Least squares mean · units on a scale
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Stiffness Subdomain Score: Change From Baseline to Each Visit
units on a scalePlaceboABT-981
Week 2-0.74 (-1.692 to 0.215)-0.96 (-1.877 to -0.036)
Week 4-0.98 (-1.937 to -0.028)-1.24 (-2.163 to -0.321)
Week 8-1.51 (-2.535 to -0.493)-1.43 (-2.412 to -0.441)
Week 12-1.65 (-2.706 to -0.599)-1.23 (-2.244 to -0.211)
Week 16-1.76 (-2.885 to -0.633)-1.61 (-2.695 to -0.522)
Week 20-1.34 (-2.515 to -0.169)-1.85 (-2.986 to -0.722)
Week 26-1.94 (-3.017 to -0.859)-2.45 (-3.492 to -1.410)
Statistical analysis
  • Placebo vs ABT-981 · ANCOVA · p = 0.719 (P-value for test of difference in change from baseline between ABT-981 dose group and placebo is from an ANCOVA model with treatment group and country as the main factors and baseline as a covariate.) · Ls mean difference: 0.15 · 95% CI -0.677 to 0.979
SecondaryAustralian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Total Score: Change From Baseline to Each Visit

The AUSCAN NR3.1 is a self-report measure composed of a battery of 15 questions assessing the three dimensions of pain (5 questions), joint stiffness (1 question) and physical function (9 questions) using an 11-box Numerical Rating Scale (NRS-11) from 0 (low) to 10 (high). The total score ranges from 0 to 150; lower scores indicate better status. A decrease in the total score represents improvement in status. LOCF: Missing responses were imputed by calculation based on the last nonmissing postbaseline component values.

Time frame:
Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Reported as:
Least squares mean · units on a scale
Australian/Canadian Hand Osteoarthritis Index (AUSCAN NR3.1) Total Score: Change From Baseline to Each Visit
units on a scalePlaceboABT-981
Week 2-10.01 (-21.037 to 1.019)-8.85 (-19.545 to 1.835)
Week 4-14.06 (-26.185 to -1.930)-12.18 (-23.928 to -0.439)
Week 8-24.52 (-36.660 to -12.373)-16.65 (-28.406 to -4.886)
Week 12-22.29 (-34.714 to -9.873)-15.15 (-27.181 to -3.124)
Week 16-29.37 (-42.469 to -16.264)-25.12 (-37.808 to -12.429)
Week 20-19.68 (-32.894 to -6.458)-22.33 (-35.128 to -9.526)
Week 26-24.73 (-38.636 to -10.820)-28.99 (-42.461 to -15.523)
Statistical analysis
  • Placebo vs ABT-981 · ANCOVA · p = 0.387 (P-value for test of difference in change from baseline between ABT-981 dose group and placebo is from an ANCOVA model with treatment group and country as the main factors and baseline as a covariate.) · Ls mean difference: 4.25 · 95% CI -5.448 to 13.945
SecondaryParticipant Assessment of Index Hand Pain Intensity Using Numeric Rating Scale (NRS-11): Change From Baseline to Each Visit

Participants rated the pain intensity of each hand during the previous 48 hours using an 11-point scale (NRS-11). The change from baseline to each visit in NRS-11 in the index hand (the hand with the most disease) are presented. Scores range from 0 to 10 points, with higher scores indicating greater pain intensity. A decrease in the NRS-11 score represents a decrease in pain intensity.

Time frame:
Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Reported as:
Least squares mean · units on a scale
Participant Assessment of Index Hand Pain Intensity Using Numeric Rating Scale (NRS-11): Change From Baseline to Each Visit
units on a scalePlaceboABT-981
Week 2-0.62 (-1.550 to 0.320)-0.69 (-1.613 to 0.228)
Week 4-1.18 (-2.163 to -0.195)-1.06 (-2.025 to -0.088)
Week 8-2.40 (-3.339 to -1.465)-1.74 (-2.660 to -0.814)
Week 12-1.65 (-2.434 to -0.875)-0.81 (-1.629 to 0.010)
Week 16-2.05 (-3.085 to -1.017)-1.60 (-2.626 to -0.578)
Week 20-1.61 (-2.749 to -0.477)-1.75 (-2.892 to -0.612)
Week 26-2.02 (-3.132 to -0.901)-2.52 (-3.620 to -1.415)
Statistical analysis
  • Placebo vs ABT-981 · ANCOVA · p = 0.281 (P-value for test of difference in change from baseline between ABT-981 dose group and placebo is from an ANCOVA model with treatment group and country as the main factors and baseline as a covariate.) · Ls mean difference: 0.45 · 95% CI -0.373 to 1.272
SecondaryPatient Global Assessment of Hand Osteoarthritis (OA) Status by NRS-11: Change From Baseline to Each Visit

Participants were asked how much they were affected by hand OA by responding to the question "Considering all the ways your hand OA affects you, how have you been during the last 48 hours?" using an 11-point scale (NRS-11). Scores range from 0 to 10 points, with higher scores indicating greater effect of hand OA on the participant. A decrease in the NRS-11 score represents an improvement the effect of hand OA on the participant.

Time frame:
Week 0 (Baseline) and Weeks 2, 4, 8, 12, 16, 20, and 26
Reported as:
Least squares mean · units on a scale
Patient Global Assessment of Hand Osteoarthritis (OA) Status by NRS-11: Change From Baseline to Each Visit
units on a scalePlaceboABT-981
Week 2-0.52 (-1.399 to 0.351)-0.54 (-1.403 to 0.316)
Week 4-1.31 (-2.277 to -0.335)-1.13 (-2.083 to -0.176)
Week 8-1.85 (-2.740 to -0.952)-1.20 (-2.080 to -0.324)
Week 12-1.78 (-2.567 to -0.993)-1.17 (-1.997 to -0.348)
Week 16-2.20 (-3.225 to -1.185)-1.69 (-2.697 to -0.677)
Week 20-1.73 (-2.836 to -0.627)-1.77 (-2.879 to -0.666)
Week 26-2.00 (-3.133 to -0.874)-2.35 (-3.465 to -1.236)
Statistical analysis
  • Placebo vs ABT-981 · ANCOVA · p = 0.212 (P-value for test of difference in change from baseline between ABT-981 dose group and placebo is from an ANCOVA model with treatment group and country as the main factors and baseline as a covariate.) · Ls mean difference: 0.52 · 95% CI -0.300 to 1.336

Adverse events

Collected over Treatment-emergent adverse events (TEAEs) and serious adverse events (TESAEs) were collected from first dose of study drug until 70 days after the last dose of study drug (up to 34 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/67 (3%)45/67 (67.2%)
ABT-981—2/64 (3.1%)49/64 (76.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboABT-981
FAECES DISCOLOUREDGastrointestinal disorders0/671/64
HAEMOGLOBIN DECREASEDInvestigations0/671/64
CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders0/671/64
ACUTE CORONARY SYNDROMECardiac disorders1/670/64
INVASIVE BREAST CARCINOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)1/670/64
Most frequent other events
Showing 10 of 17
Most frequent other events
EventPlaceboABT-981
NASOPHARYNGITISInfections and infestations17/6713/64
HEADACHENervous system disorders17/6710/64
BACK PAINMusculoskeletal and connective tissue disorders11/673/64
NAUSEAGastrointestinal disorders2/678/64
INJECTION SITE ERYTHEMAGeneral disorders0/677/64
INJECTION SITE RASHGeneral disorders3/677/64
INJECTION SITE REACTIONGeneral disorders3/677/64
NEUTROPENIABlood and lymphatic system disorders0/676/64
DIARRHOEAGastrointestinal disorders6/674/64
ARTHRALGIAMusculoskeletal and connective tissue disorders6/674/64

Baseline characteristics

Modified intent-to-treat (mITT) population: all randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)PlaceboABT-981Total
Mean65.8 ± 7.32565.7 ± 8.13265.7 ± 7.700
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboABT-981Total
Female5853111
Male91120
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kloppenburg M, Peterfy C, Haugen IK, Kroon F, Chen S, Wang L, Liu W, Levy G, Fleischmann RM, Berenbaum F, van der Heijde D, Bansal P, Wittoek R, Feng S, Fang Y, Saltarelli M, Medema JK, Levesque MC. Phase IIa, placebo-controlled, randomised study of lutikizumab, an anti-interleukin-1alpha and anti-interleukin-1beta dual variable domain immunoglobulin, in patients with erosive hand osteoarthritis. Ann Rheum Dis. 2019 Mar;78(3):413-420. doi: 10.1136/annrheumdis-2018-213336. Epub 2018 Dec 14. PubMed 30552176 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Jul 2016, 16 months.

Results were first posted in Jul 2017, 1 year after primary completion.

Of 54 industry-sponsored phase 2 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 16 months is close to that.

Counting every sponsor, half of 82 studies reached it within 19 months; a quarter within 10 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2015
First posted
Mar 10, 2015
StartActual
Mar 2015
Primary completionActual
Jul 2016
CompletionActual
Jul 2016
Results first posted
Jul 13, 2017
Last update
Aug 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02384538
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 10, 2015
Start date
Mar 2015
Primary completion
Jul 2016
Completion
Jul 2016
Results posted
Jul 13, 2017
Last update
Aug 11, 2017

Study contacts

AbbVie Inc
study director · AbbVie

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lutikizumab

Start the discussion